Kiernan A. Seth's most recent trade in Lexicon Pharmaceuticals Inc was a trade of 22,963 Restricted Stock Units done . Disclosure was reported to the exchange on Feb. 28, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lexicon Pharmaceuticals Inc | Kiernan A. Seth | VP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 22,963 | 45,927 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Kiernan A. Seth | VP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 22,963 | 64,949 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Kiernan A. Seth | VP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 14,833 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Kiernan A. Seth | VP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 14,833 | 36,700 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Kiernan A. Seth | VP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.17 per share. | 28 Feb 2023 | 11,813 | 53,136 (0%) | 0% | 2.2 | 25,634 | Common Stock |
| Lexicon Pharmaceuticals Inc | Kiernan A. Seth | VP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 5,286 | 5,287 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Kiernan A. Seth | VP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 5,286 | 41,986 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Kiernan A. Seth | VP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 280,100 | 280,100 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Kiernan A. Seth | VP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 93,370 | 93,370 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Kiernan A. Seth | VP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 14,834 | 24,841 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Kiernan A. Seth | VP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 14,834 | 14,833 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Kiernan A. Seth | VP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 10,007 | 10,007 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Kiernan A. Seth | VP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 10,007 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Kiernan A. Seth | VP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.85 per share. | 28 Feb 2022 | 8,261 | 21,867 (0%) | 0% | 2.9 | 23,544 | Common Stock |
| Lexicon Pharmaceuticals Inc | Kiernan A. Seth | VP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 5,287 | 10,573 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Kiernan A. Seth | VP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 5,287 | 30,128 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Kiernan A. Seth | VP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 206,670 | 206,670 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Kiernan A. Seth | VP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 68,890 | 68,890 | - | - | Restricted Stock Units |